Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641908 · ClinicalTrials.gov registry record · Phase 1
Anti-GD2 ADC M3554 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 11
- Study locations
NCT06641908: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by EMD Serono Research & Development Institute.
NCT06641908 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 52 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06641908, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Conditions Studied
Interventions
- DRUG M3554
Study Locations (11)
Other
- UZ Leuven - Leuven
- Institut Bergonié - Service d'Oncologie Médicale - Bordeaux
- Centre Oscar Lambret - cancerologie generale - Lille
- Centre Leon Berard - Service d'Oncologie Medicale - Lyon
- Centre Antoine Lacassagne - Service d'Hématologie Oncologie - Nice
- National Cancer Center Hospital - Chūōku
- Universitaetsspital Zuerich - Klinik fuer Neurologie - Zurich
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc - New York
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Surrey
- Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey) - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-11-08 |
| Est. Completion | 2027-04-16 |
| Phase | Phase 1 |
What NCT06641908 shows while recruiting
NCT06641908 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which M3554 is the first listed.
NCT06641908 lists 11 locations in 5 states (Other, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT06641908 about?
NCT06641908 is a clinical study titled "Anti-GD2 ADC M3554 in Advanced Solid Tumors". The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
What is the current status of trial NCT06641908?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-11-08. Estimated completion is 2027-04-16.
What conditions does trial NCT06641908 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06641908?
The interventions under investigation include: M3554 (DRUG).
Who is sponsoring clinical trial NCT06641908?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641908 being conducted?
This trial has 11 study locations across Massachusetts, New York, Texas, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06641908's enrollment target sits among peer trials
52 155th of 189 higher than 32 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI